0 results available. Select is focused ,type to refine list, press Down to open the menu,
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, an...
The following section summarizes insights on Amgen Inc's Debt / Common Equity:
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Debt / Common Equity in the risk category include:
A ratio that measures the level of the debt relative to the book value of common equity.
Debt / Equity is defined as:
Total Debt
(/) Total Common Equity
(=) Debt / Equity
Debt / Equity for Amgen is calculated as follows:
Total Debt [ 60.879 B]
(/) Total Common Equity [ 5.877 B ]
(=) Debt / Equity [ 1,035.9% ]
The tables below summarizes the trend in Amgen’s Debt / Equity over the last five years:
| Fiscal Year | Total Debt | Total Common Equity | Debt / Equity |
|---|---|---|---|
| 2020-12-31 | 33.445 B | 9.409 B | 355.5% |
| 2021-12-31 | 33.979 B | 6.7 B | 507.1% |
| 2022-12-31 | 39.64 B | 3.661 B | 1,082.8% |
| 2023-12-31 | 65.423 B | 6.232 B | 1,049.8% |
| 2024-12-31 | 60.879 B | 5.877 B | 1,035.9% |
The tables below summarizes the trend in Amgen’s Debt / Equity over the last four quarters:
| Fiscal Quarter | Total Debt | Total Common Equity | Debt / Equity |
|---|---|---|---|
| 2024-03-31 | 64.02 B | 5.022 B | 1,274.8% |
| 2024-06-30 | 62.645 B | 5.925 B | 1,057.3% |
| 2024-09-30 | 60.398 B | 7.527 B | 802.4% |
| 2024-12-31 | 60.879 B | 5.877 B | 1,035.9% |
The higher the ratio, the more debt the company has in its capital structure.
Read More on HBR: Debt / Equity Ratio